Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
Oncogenic kinases contribute to immunosuppression and modulate the tumor microenvironment in solid tumors. Increasing evidence supports the fundamental role of oncogenic kinase signaling networks in coordinating immunosuppressive tumor microenvironments. This has led to numerous studies examining th...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/5/2608 |
| _version_ | 1797413893214044160 |
|---|---|
| author | Ryuhjin Ahn Josie Ursini-Siegel |
| author_facet | Ryuhjin Ahn Josie Ursini-Siegel |
| author_sort | Ryuhjin Ahn |
| collection | DOAJ |
| description | Oncogenic kinases contribute to immunosuppression and modulate the tumor microenvironment in solid tumors. Increasing evidence supports the fundamental role of oncogenic kinase signaling networks in coordinating immunosuppressive tumor microenvironments. This has led to numerous studies examining the efficacy of kinase inhibitors in inducing anti-tumor immune responses by increasing tumor immunogenicity. Kinase inhibitors are the second most common FDA-approved group of drugs that are deployed for cancer treatment. With few exceptions, they inevitably lead to intrinsic and/or acquired resistance, particularly in patients with metastatic disease when used as a monotherapy. On the other hand, cancer immunotherapies, including immune checkpoint inhibitors, have revolutionized cancer treatment for malignancies such as melanoma and lung cancer. However, key hurdles remain to successfully incorporate such therapies in the treatment of other solid cancers. Here, we review the recent literature on oncogenic kinases that regulate tumor immunogenicity, immune suppression, and anti-tumor immunity. Furthermore, we discuss current efforts in clinical trials that combine kinase inhibitors and immune checkpoint inhibitors to treat breast cancer and other solid tumors. |
| first_indexed | 2024-03-09T05:25:31Z |
| format | Article |
| id | doaj.art-a8cb3183b12f42deaf8d0557290f92e1 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T05:25:31Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-a8cb3183b12f42deaf8d0557290f92e12023-12-03T12:37:23ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-03-01225260810.3390/ijms22052608Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid TumorsRyuhjin Ahn0Josie Ursini-Siegel1Department of Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USADepartment of Biochemistry, McGill University, Montréal, QC H3G 1Y6, CanadaOncogenic kinases contribute to immunosuppression and modulate the tumor microenvironment in solid tumors. Increasing evidence supports the fundamental role of oncogenic kinase signaling networks in coordinating immunosuppressive tumor microenvironments. This has led to numerous studies examining the efficacy of kinase inhibitors in inducing anti-tumor immune responses by increasing tumor immunogenicity. Kinase inhibitors are the second most common FDA-approved group of drugs that are deployed for cancer treatment. With few exceptions, they inevitably lead to intrinsic and/or acquired resistance, particularly in patients with metastatic disease when used as a monotherapy. On the other hand, cancer immunotherapies, including immune checkpoint inhibitors, have revolutionized cancer treatment for malignancies such as melanoma and lung cancer. However, key hurdles remain to successfully incorporate such therapies in the treatment of other solid cancers. Here, we review the recent literature on oncogenic kinases that regulate tumor immunogenicity, immune suppression, and anti-tumor immunity. Furthermore, we discuss current efforts in clinical trials that combine kinase inhibitors and immune checkpoint inhibitors to treat breast cancer and other solid tumors.https://www.mdpi.com/1422-0067/22/5/2608kinase signalingbreast cancersolid tumorsanti-tumor immunityimmunosuppressionkinase inhibitors |
| spellingShingle | Ryuhjin Ahn Josie Ursini-Siegel Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors International Journal of Molecular Sciences kinase signaling breast cancer solid tumors anti-tumor immunity immunosuppression kinase inhibitors |
| title | Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors |
| title_full | Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors |
| title_fullStr | Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors |
| title_full_unstemmed | Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors |
| title_short | Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors |
| title_sort | clinical potential of kinase inhibitors in combination with immune checkpoint inhibitors for the treatment of solid tumors |
| topic | kinase signaling breast cancer solid tumors anti-tumor immunity immunosuppression kinase inhibitors |
| url | https://www.mdpi.com/1422-0067/22/5/2608 |
| work_keys_str_mv | AT ryuhjinahn clinicalpotentialofkinaseinhibitorsincombinationwithimmunecheckpointinhibitorsforthetreatmentofsolidtumors AT josieursinisiegel clinicalpotentialofkinaseinhibitorsincombinationwithimmunecheckpointinhibitorsforthetreatmentofsolidtumors |